University Hospital Regensburg, Department of Pediatric Hematology and Oncology
Welcome,         Profile    Billing    Logout  
 2 Trials 
2 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Corbacioglu, Selim
THRIVE-132, NCT04927247: A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

Terminated
3
72
Europe, US, RoW
Inclacumab, Placebo
Pfizer
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
11/23
11/23
THRIVE-131, NCT04935879: A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

Completed
3
243
Europe, US, RoW
Inclacumab, Placebo
Pfizer
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis
06/24
06/24

Download Options